*Final Program as at 19 February, 2017

Download the Final Program
Thursday, 2 March, 2017
16:00-18:00 Registration
18:00-19:00 Get-Together Reception
 
Friday, 3 March, 2017
07:30 Registration
09:00-09:15  Opening Ceremony Hall A
  Greetings by:
Prof. Talma Rosenthal, Israel, Honorary Chair
Prof. Giuseppe Mancia, Italy, Honorary Chair
Prof. Reuven Zimlichman, Israel, Chair
 09:15-10:30 Plenary Session 1: Fixed Combination and Cardiovascular Disease
Chairs: Talma Rosenthal, Israel; Alberto Zanchetti, Italy
 Hall A
 09:15 Long Term Advantages of Initial Combination Treatment: New Evidence
Giuseppe Mancia, Emeritus Professor of Medicine University of Milano Bicocca, Milano, Italy
09:40 Combination Therapy in the Cardiometabolic Syndrome: Past, Present and Future
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel
 10:05 Can a Polypill, One Single Tablet, Combat Different Cardiovascular Risk Factors?
Talma Rosenthal, Sackler Faculty of Medicine, Tel Aviv University, Israel
10:30-11:00  Coffee Break, Exhibition Visit and Posters Viewing
 11:00-12:20 Plenary Session 2: Hypertension and Combination Therapy
Chairs: Giuseppe Mancia, Italy; Reuven Zimlichman, Israel
 Hall A
11:00 Benefits and Burdens of Antihypertensive Treatment: Meta-Analyses of Randomized Controlled Trials
Alberto Zanchetti, Emeritus Professor of Internal Medicine at the University of Milan, Italy
 11:25  Inhibition of SGLT-2 and Antihypertensive Treatment Strategies: New Mechanisms of Cardiovascular Protection
Jan Menne, Dept. of Nephrology and Hypertension Medicine, University of Hannover, Hannover Medical School, Germany
11:50 Vascular Biology of Hypertension: Clinical Implications
Rhian M. Touyz, Institute of Cardiovascular Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK
12:15  Discussion
12:30-13:30 Lunch Break, Exhibition Visit and Posters Viewing
13:30-15:30 Plenary Session 3: Hypertension and Metabolic Syndrome
Chairs: Rhian M. Touyz, UK; Jan Menne, Germany

Hall A
13:30 Arterial Destiffening in Hypertensive Patients with Type 2 Diabetes
Stephane Laurent, Dept. of Clinical Pharmacology in the Hôpital Européen Georges Pompidou, France
13:55 Metabolic Syndrome: Does it Exist?
Dimitri Mikhailidis, University College London, UK
14:20 Target BP in the Elderly and use of Combination Treatment
Enrico Agabiti-Rosei, Dept. of Medical and Surgical Sciences, University of Brescia, Italy
14:45 From Epidemiological Transition to Modern Cardiovascular Epidemiology: Hypertension in the 21st Century
Jacques Blacher, Hypertension and cardiovascular prevention unit, Hôtel-Dieu university Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France
15:10 Correct Combinations of Antihypertensive Drugs According to the Principles of Clinical Pharmacology
Stefano Taddei, Dept. of Clinical and Experimental Medicine, University of Pisa, Italy
15:30-16:00 Coffee Break, Exhibition Visit and Posters Viewing
 16:00-17:00 Plenary Session 4: The Kidney and Vascular Disease
Chairs: Jean-Michel Halimi, France; Dimitri Mikhailidis, UK

 Hall A
16:00 Combination Antihypertensive Therapy in Chronic Kidney Disease: Does SPRINT Tell us the Truth?
Alexander Kirsch, Medical University Graz, Department of Internal Medicine,
Clinical Division of Nephrology, Graz, Austria
16:20 Which Combination Therapy in the Renal Patient?
Jean-Michel Halimi, Service de Néphrologie-Immunologie Clinique, Hôpital Bretonneau, Tours cedex, France
16:40 Total Cardiovascular Risk Evaluation and Management in patients with PAD
Marianne Brodmann, Dept. of Internal Medicine, Medical University Graz, Austria
Saturday, 4 March, 2016
07:30 Registration
08:45-10:00 Plenary Session 5: Heart Failure and Hemodynamics
Chairs: Damiano Rizzoni, Italy; Jean-Michel Halimi, France

Hall A
08:45 Need for Pleitropic Therapy in Chronic Heart Failure
Dirk L. Brutsaert, Professor-Emeritus, University of Antwerp, Antwerp, Belgium
09:10 Optimal Treatment of Heart Failure: Is there a Place of Combination Therapy?
Amitai Elkayam, Assuta Medical Center, Tel Aviv, Israel
09:35 Cross-Talk between Microcirculation and Macrocirculation: Effects of Combination Treatment
Damiano Rizzoni, Dept. of Medical and Surgical Sciences, University of Brescia, Italy
10:00-10:30 Coffee Break, Exhibition Visit and Posters Viewing
   
10:30-11:10 Plenary Session 6: Lipids and Combination Therapy
Chairs: Dirk L. Brutsaert, Belgium, Amitai Elkayam, Israel
Hall A
10:30 PCSK9: Together or Alone? Current State of Knowledge 2017
Maciej Banach, Dept. of Hypertension, Medical University of Lodz, Poland
10:50 Advance towards Personalized Treatment for Prevention of Atherosclerotic Cardiovascular Disease: Genetics Proteomics Immunology and Optimal Choice of Treatment, the Future is here
Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel
11:10-12:25 Plenary Session 7: Free Communications 
Chairs: Damiano Rizzoni, Italy; Reuven Zimlichman, Israel
Hall A
11:10 Use of Polypill Components among a Swiss Population-Based Study
Julien Castioni, Dept. of Medicine, Internal Medicine, Lausanne University Hospital, Switzerland
11:25 Fixed Dose Combination Olmesartan/Amlodipine Decreases Blood Pressure and Improves Ventricular-Arterial Coupling
Iana Simova, Dept. of Cardiology, Acibadem City Clinic – University Hospital, Bulgaria
11:40 Antihypertensive Efficacy and Uric Acid Lowering Effect of the Combination of Losartan Hydrochlorothiazide and Amlodipine Compared with a Combination of Bisoprolol Hydrochlorothiazide and Amlodipine
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine
11:55 A Cross Sectional Study of Metformin Induced Vitamin B12 Deficiency in Metabolic Syndrome Patients among North Indian Rural Population
Hariharan Munganda, Internal Medicine and Endocrinology, Asian Institute of Medical Sciences, India
12:10 Rosuvastatin / Olmesartan FDC for the Treatment of CAD
Vuong Trieu, Clinical Research, Stocosil, USA
12:30-13:30 Lunch Break, Exhibition Visit and Posters Viewing
13:30-15:30 Plenary Session 8: Diabetes and Combination Therapy
Chairs: Maciej Banach, Poland; Bernard I. Levy, France

Hall A
13:30 Outcomes of iGlarLixi, a Titratable Fixed-ratio Combination of Insulin Glargine / Lixisenatide, versus Insulin Glargine and Lixisenatide by Baseline Characteristics: LixiLan-O Trial
Bruno Guerci, University of Lorraine and Brabois Adult Hospital, Vandœuvre-lès-Nancy, France
13:50 Fixed Dose Combinations with Empagliflozin
Eberhard Standl, Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany
14:10 Arguments for Early Fixed-Dose Glucose Lowering Combination Therapies
Guntram Schernthaner, Dept. of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
14:30 Why and How do We Have to Use Drugs Combinations for Treatment of Hypertensive Patients
Bernard I. Levy, Emeritus Professor of Physiology, France
14:50 New Opportunities from GLP-1 RA Combination Therapies in Type 2 Diabetes
Francesco Giorgino, University of Bari Aldo Moro, Bari, Italy
15:10 Discussion
15:30-16:00 Coffee Break, Exhibition Visit and Posters Viewing
16:00-16:50 Plenary Session 9: Therapy and Hypertension Therapy
Chairs: Guntram Schernthaner, Austria; Dov Gavish, Israel
Hall A
16:00 Novel Combination Therapy in Hypertension: Chlorthalidone with Spironolactone
Uday Jadhav, Dept. of Cardiology, MGM New Bombay Hospital, Vashi, India
16:25 HOPE-3: Efficacy and Safety of Combined BP and Lipid Lowering for Primary Prevention of Cardiovascular Disease
Basil S. Lewis, Lady Davis Carmel Medical Center, The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel
Sunday, 5 March, 2017
08:00 Registration
08:30-10:00 Plenary Session 10: Combination and Cardiovascular Disease
Chairs: Flávio D. Fuchs, Brazil;Andrzej Januszewicz, Poland

Hall A
08:30 Cardiovascular Outcome Trials in Diabetes: Cardiologist’s Point of View
Francesco Cosentino, Cardiology Unit, Dept. of Medicine, Karolinska University Hospital, Solna, Sweden
08:55 Combination Therapy in the Management of Stable Coronary Artery Disease in the PCI Era
Giuseppe Ambrosio, Dept. of Cardiology, University of Perugia School of Medicine, Perugia, Italy
09:20 What is the Optimal Two-Drug and Three-Drug Fixed Combination?
Andrzej Januszewicz, Dept. of Hypertension, Institute of Cardiology, Warsaw, Poland
09:35 Comparison of the Effects of Zofenopril or Ramipril Plus Acetylsalicylic Acid in Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction
Salvatore Novo, Dept. of Internal Medicine and Cardiovascular Disease, University of Palermo, Italy
10:00-10:30 Coffee Break, Exhibition Visit and Posters Viewing
10:30-12:30 Closing Plenary Session 11: Combination Therapy
Chairs: Talma Rosenthal, Israel; Reuven Zimlichman, Israel

Hall A
10:30 Amiloride, an Obligatory Companion of Chlorthalidone and other Diuretics
Flávio D. Fuchs, Hospital de Clinicas de Porto Alegre, Brazil
10:55 Combination Therapy and Kidney Outcome-What should be the Target?
Bojan Jelakovic, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
11:20 The Role of Combination Therapy to Lipid Targets: Is Getting to Target Levels enough or do the Means to Get there Affect Outcome and Safety? Lessons from Recent Studies (improve it and more)
Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel
11:45 Combination Therapy in the Hypertensive Patient with Coronary Artery Disease
Paolo Palatini, Dept. of Medicine, Vascular Medicine, University of Padova, Italy
12:10 Conclusion
Poster Presentations
 1 Risk of Obstructive Sleep Apnea among Patients with Type 2 Diabetes in Saudi Arabia
Metab Algeffari, Family Medicine Department, Qassim University College of Medicine, Saudi Arabia
 2 A Fixed Combination of Lisinopril and Amlodipine in the Treatment of Overweight Patients with Arterial Hypertension and Coronary Heart Disease
Albert Galyavich, Dept. of Cardiology, Kazan State Medical University, Russia
3 Fixed Antihypertensive Combination Amlodipine/Indapamide Reduces Amlodipine-Induced Lower Leg Edema
Iana Simova, Dept. of Cardiology, National Multiprofile Transport Hospital Tsar Boris III, Bulgaria
4 Assessment of Quality of Life And Co Morbidity Resolution after Laparoscopic Sleeve Gastrectomy in Obese North Indian Population-A Prospective Single Institution Study
Amal Pushp Singh, General Surgery, Asian Institute of Medical Sciences, India
5 Combination of Lisinopril Hydrochlorothiazide and Amlodipineof Ukrainian Production Effectively Lowers Blood Pressure and Central Brahialnoho
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine
6 The Influemce of Metabolic Factors on Central Blood Pressure Lowering Effect of Lisnopril or Bisoprolol Plus Hydrochlorthiazide and Amlodipine
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine
7 Celecoxib FDCs for the treatment of Arthritis
Vuong Trieu, R&D, Marina Biotech, USA
8 Add-on Empagliflozin Therapy (Alone or in Fixed Combination) Can Reduce the Risk of Cardiovascular Disease in People with TYPE 2 Diabetes
Katarina Vukelic, Dept of Diabetes, Health Centre Grosuplje, Slovenia
9 The Association of Pediatric Obesity with Dyslipidemia, Type 2 Diabetes and Hypertension
Michael Yafi, Dept. of Pediatrics, the University of Texas at Houston Health Science Center, USA
10 Effects of the Fixed Combination of Losartan and Hydrochlorothiazide on Blood Pressure in Hypertensive Patients with Diabetic Nephropathy
Gen Yasuda, Dept. of Nephrology, Yokohama City University, Japan